LPD002 / Lepu Biopharma - LARVOL DELTA

LPD002, a novel anti-PD-1/IL-2 fusion protein, demonstrates potent antitumor activity in preclinical studies (AACR 2026) - "LPD002 represents a novel immunotherapeutic strategy that integrates PD-1 blockade with tumor-focused IL-2 activation, eliciting potent anti-tumor activity while reducing systemic toxicity. These preclinical findings demonstrate that LPD002 is a promising therapeutic candidate for solid tumors and warrants further clinical investigation."

Preclinical • Oncology • Solid Tumor • CD4 • CD8 • IL2